Search research articles
Contact Us
Filters
Showing results (81-90 of 116) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study
Carlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Cancer Biology & Therapy
|
November 25, 2010
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study
Carlos Hörndler, Rosa Gallego, Xabier García-Albeniz, et al.
The Oncologist
|
September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial
Carlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Joana Vidal, David Casadevall, Beatriz Bellosillo, et al.
Neoplasia (New York, N.Y.)
|
May 30, 2018
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, et al.
Oncogene
|
October 8, 2021
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
Alfonso García-Valverde, Jordi Rosell, Sergi Sayols, et al.
The Oncologist
|
June 26, 2019
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
Xabier García-Albéniz, Vicente Alonso, Pilar Escudero, et al.
Oncotarget
|
October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysis
Marion Savina, Saskia Litière, Antoine Italiano, et al.
Annals of Surgical Oncology
|
January 23, 2015
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)
Jordi Rubió-Casadevall, Javier Martinez-Trufero, Xabier Garcia-Albeniz, et al.
Cancer Medicine
|
December 19, 2019
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 116) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study
Carlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Cancer Biology & Therapy
|
November 25, 2010
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study
Carlos Hörndler, Rosa Gallego, Xabier García-Albeniz, et al.
The Oncologist
|
September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial
Carlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Joana Vidal, David Casadevall, Beatriz Bellosillo, et al.
Neoplasia (New York, N.Y.)
|
May 30, 2018
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, et al.
Oncogene
|
October 8, 2021
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
Alfonso García-Valverde, Jordi Rosell, Sergi Sayols, et al.
The Oncologist
|
June 26, 2019
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
Xabier García-Albéniz, Vicente Alonso, Pilar Escudero, et al.
Oncotarget
|
October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysis
Marion Savina, Saskia Litière, Antoine Italiano, et al.
Annals of Surgical Oncology
|
January 23, 2015
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)
Jordi Rubió-Casadevall, Javier Martinez-Trufero, Xabier Garcia-Albeniz, et al.
Cancer Medicine
|
December 19, 2019
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, et al.
Page
of 12